Monthly Newsletter

Innovation and growth remain a priority to support customers and COVID-19 initiatives

FUJIFILM Irvine Scientific, Inc. is celebrating its 50th year of providing innovative cell culture media products and services. Since its formation, the Company has established a reputation as an innovator and leader in providing cell culture solutions for the Life Science and Medical markets.

From its inception in the 1970s as a fetal bovine serum supplier, the Company has continuously provided pioneering cell culture solutions. In the 1980s it revolutionized embryo culture with commercially available media for in vitro fertilization (IVF) clinics worldwide. In the 1990s, the Company brought chemically defined media to biotherapeutic manufacturers. Most recently FUJIFILM Irvine Scientific launched products which better support cell culture-based vaccine production, and advanced cell and gene therapy applications. Since its acquisition by FUJIFILM Corporation, the Company has expanded its global reach and manufacturing capacity more rapidly. This expansion positions the Company to meet the growing needs of Life Science and Medical customers.

“We have reflected on our trailblazing history and many contributions over the last five decades. Our 50th year coincided with unprecedented challenges from the COVID-19 pandemic.”, said Yutaka Yamaguchi, CEO and Chairman of the Board, FUJIFILM Irvine Scientific. “We are grateful for the dedication and commitment shown by our employees to uphold our standards of delivering the highest quality products and service under these difficult conditions. We are also humbled by the extraordinary efforts of the community we serve in the fight against the virus and honored that our customers trust FUJIFILM Irvine Scientific to provide the critical cell culture media needed to manufacture lifesaving therapies and vaccines, and to support medical applications. We are inspired to continue our mission to improve health through innovation, partnership, and service for the next 50 years.”

Tim Mullane, President and COO, FUJIFILM Irvine Scientific, commented: “Our history in Medical and Life Science applications includes many firsts and cell culture improvements. These advances have allowed our customers to achieve better and more consistent results from their cell culture, which in turn has fueled tremendous Company growth. The pandemic has required us to accelerate plans for production capacity expansion. We doubled our capacity in California and expect production from our Netherlands facility before the end of 2021. During this pronounced demand for COVID-19 therapies and vaccines our entire organization is motivated to support programs, such as collaborations with the U.S. government, and others combatting the pandemic.”

About FUJIFILM Irvine Scientific

FUJIFILM Irvine Scientific, Inc., is a worldwide leader in the innovation and manufacture of cell culture media, reagents, and medical devices for researchers and clinicians. The company provides unrivaled service and quality to scientists working in biopharmaceuticals, cell therapy, and regenerative medicine, assisted reproductive technology and cytogenetics, and industrial cell culture for the large-scale production of biotherapeutics and vaccines. FUJIFILM Irvine Scientific adheres to both ISO and FDA regulations and operates dual cGMP manufacturing facilities in California, USA, and Tokyo, Japan. The company’s consultative philosophy combined with expertise in cell culture and compliance provides customers with unique capabilities and support. For over 50 years, FUJIFILM Irvine Scientific has remained uniquely flexible and focused on media while becoming a strategic global leader in media products and services.  FUJIFILM Irvine Scientific, Inc. is a subsidiary of FUJIFILM Holdings America Corporation reporting to FUJIFILM Holdings Corporation.

About FUJIFILM Holdings Corporation

FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2020, the company had global revenues of $21 billion, at an exchange rate of 109 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship.